The Chinese University of Hong Kong

About: The Chinese University of Hong Kong is a education organization based out in Hong Kong, China. It is known for research contribution in the topics: Population & Cancer. The organization has 43411 authors who have published 93672 publications receiving 3066651 citations.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Abstract: Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS). Patients and Methods In this phase III study, eligible patients with stage IIIB/IV lung adenocarcinoma were screened for EGFR mutations. Mutation-positive patients were stratified by mutation type (exon 19 deletion, L858R, or other) and race (Asian or non-Asian) before two-to-one random assignment to 40 mg afatinib per day or up to six cycles of cisplatin plus pemetrexed chemotherapy at standard doses every 21 days. The primary end point was PFS by independent review. Secondary end points included tumor response, overall survival, adverse events, and patient-reported outcomes (PROs). Results A total of 1,269 patients were screened, and 345 were randomly assigned to treatment. Median PFS was 11.1 months for afatinib and 6.9 months for chemotherapy (hazard ratio [HR], 0.58; 95% CI, 0.43 to 0.78; P = .001). Median PFS among those with exon 19 deletions and L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). The most common treatmentrelated adverse events were diarrhea, rash/acne, and stomatitis for afatinib and nausea, fatigue, and decreased appetite for chemotherapy. PROs favored afatinib, with better control of cough, dyspnea, and pain. Conclusion Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Abstract: BackgroundOsimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non–small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. MethodsIn this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non–small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed pro...

Learning to Detect a Salient Object

Abstract: In this paper, we study the salient object detection problem for images. We formulate this problem as a binary labeling task where we separate the salient object from the background. We propose a set of novel features, including multiscale contrast, center-surround histogram, and color spatial distribution, to describe a salient object locally, regionally, and globally. A conditional random field is learned to effectively combine these features for salient object detection. Further, we extend the proposed approach to detect a salient object from sequential images by introducing the dynamic salient features. We collected a large image database containing tens of thousands of carefully labeled images by multiple users and a video segment database, and conducted a set of experiments over them to demonstrate the effectiveness of the proposed approach.

ESRGAN: Enhanced Super-Resolution Generative Adversarial Networks

Abstract: The Super-Resolution Generative Adversarial Network (SRGAN) is a seminal work that is capable of generating realistic textures during single image super-resolution. However, the hallucinated details are often accompanied with unpleasant artifacts. To further enhance the visual quality, we thoroughly study three key components of SRGAN – network architecture, adversarial loss and perceptual loss, and improve each of them to derive an Enhanced SRGAN (ESRGAN). In particular, we introduce the Residual-in-Residual Dense Block (RRDB) without batch normalization as the basic network building unit. Moreover, we borrow the idea from relativistic GAN to let the discriminator predict relative realness instead of the absolute value. Finally, we improve the perceptual loss by using the features before activation, which could provide stronger supervision for brightness consistency and texture recovery. Benefiting from these improvements, the proposed ESRGAN achieves consistently better visual quality with more realistic and natural textures than SRGAN and won the first place in the PIRM2018-SR Challenge (region 3) with the best perceptual index. The code is available at https://github.com/xinntao/ESRGAN.

Age of onset of mental disorders: a review of recent literature

Abstract: Purpose of reviewThe aim of this article is to review recent epidemiological research on age-of-onset of mental disorders, focusing on the WHO World Mental Health surveys.Recent findingsMedian and inter-quartile range (IQR; 25th–75th percentiles) of age-of-onset is much earlier for phobias (7–14, IQ